In WT mice bearing MC38‐OVAdim tumors, CD8+ T cells and IFNγ were critical for the efficacy of the anti‐RANKL/PD‐1 BsAb therapy as depletion of CD8+ T cells or neutralisation of IFNγ in these treated mice abrogated the anti‐tumor response (Figure 4b). The gene discussed is CD8A; the disease is neoplasm.